Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.52 |
| ▸ | CA1 | P00915 | 14/20 | 0.52 |
| ▸ | CA12 | O43570 | 14/20 | 0.52 |
| ▸ | CA9 | Q16790 | 14/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949076 | 0.80 | KMT2A (0.51) | KMT2AALDH1A1SMN1; SMN2MAPTALOX12 | |
| SCHEMBL6946115 | 0.80 | NPC1 (0.49) | SMN1; SMN2 | |
| SCHEMBL11381022 | 0.79 | CA2 (0.52) | CA2CA1CA12CA9 | |
| SCHEMBL6954818 | 0.78 | GAA (0.53) | KMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL6957288 | 0.74 | MEN1 (0.52) | CA2CA9KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL11382494 | 0.73 | NPC1 (0.43) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL6949514 | 0.72 | RAB9A (0.57) | KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL11371680 | 0.71 | DPP4 (0.33) | — | |
| SCHEMBL11371771 | 0.70 | FLT1 (0.47) | CA2CA1KMT2AALDH1A1 | |
| SCHEMBL11381770 | 0.70 | ALDH1A1 (0.48) | CA2CA1ALDH1A1MAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027041-B1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | AMPLIMED INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | VALLEY VENTURES III, L.P. | 2003-07-10 | — | — | US | disclosed |
| US-6297230-B1 | N-CARBAMOYL-SUBSTITUTED | AMPLIMED, INC. | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | ABHD16A, PNLIP, LIPA | CA2 4848/4885CA1 4833/4885CA12 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.